Current Edition

Europe

Novo’s oral semaglutide outperforms Jardiance in late-stage study

Danish drugmaker Novo Nordisk said Tuesday its PIONEER 2 study testing oral semaglutide in patients with type 2 diabetes met its primary objective, showing a …

Continue Reading →